Source comparison
TB-500 Research vs Clinical-Grade Peptides: Regulatory Distinctions
Purity Standard ≥98% via HPLC ≥99% via multiple validated assays Synthesis Oversight Manufacturer quality control FDA GMP facility inspection Endotoxin Testing Optional or not disclosed Mandatory (<0.5 EU/mg) Certificate of Analysis Typically provided Provided
This comparison does not assign a generated winner or score.
- Purity Standard
- ≥98% via HPLC
- ≥99% via multiple validated assays
- Synthesis Oversight
- Manufacturer quality control
- FDA GMP facility inspection
- Endotoxin Testing
- Optional or not disclosed
- Mandatory (<0.5 EU/mg)
- Certificate of Analysis
- Typically provided
- Provided with batch traceability
- Intended Use
- In vitro or animal research only
- Human clinical trials or therapy
- Legal Status
- Not approved for human use
- Requires IND or approved NDA
- Cost Differential
- $80–$150 per 5mg vial
- $400–$800 per equivalent dose
- Bottom Line
- Research-grade peptides are not interchangeable with clinical-grade. They lack the sterility, endotoxin, and traceability documentation required for human use. Researchers must ensure their peptide source matches their experimental regulatory requirements.
- Research-grade TB-500 is synthesised for laboratory use. Not human consumption. This distinction is not semantic. Research peptides may contain trace impurities, bacterial endotoxins, or peptide fragments that do not affect in vitro experiments but would pose safety risks in human subjects. Clinical-grade peptides undergo additional purification steps, sterile filtration, and endotoxin removal to meet FDA standards for investigational new drug (IND) applications.
- The practical implication for researchers: if your institution's IRB or IACUC protocol requires clinical-grade reagents. As some human cell culture or large animal studies do. Research-grade peptides are not compliant regardless of purity percentage. Conversely, basic science research using immortalised cell lines or small animal models does not require clinical-grade peptides, and specifying them unnecessarily inflates research costs without improving experimental validity.